• Publications
  • Influence
Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
Secondary hyperparathyroidism (SHPT) is a challenge frequently encountered in the management of patients with chronic kidney disease (CKD). Downregulation of the parathyroid vitamin D andExpand
  • 328
  • 22
Normal and pathologic concentrations of uremic toxins.
An updated review of the existing knowledge regarding uremic toxins facilitates the design of experimental studies. We performed a literature search and found 621 articles about uremic toxicityExpand
  • 441
  • 21
Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo.
Fibroblastic growth factor 23 (FGF23) is a bone-derived hormone that has a pivotal role in the pathogenesis of mineral disorders in chronic kidney disease. To study the effect of parathyroid hormoneExpand
  • 122
  • 8
Quantitative analysis of acid-base balance in show jumpers before and after exercise.
The acid-base status of venous blood was studied in 17 show jumpers before and after exercise using both a traditional and a quantitative approach. Partial pressure of carbon dioxide (PCO(2)), pH,Expand
  • 49
  • 7
Osteoporosis in chronic kidney disease.
i m w m t s T c p S a a g UR UNDERSTANDING of the pathogenesis of bone disorders has progressed coniderably over the past 20 years. In individuals ith normal kidney function, the focus hasExpand
  • 172
  • 6
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement.
Under the auspices of the European Renal Best Practice, a group of European nephrologists, not serving on the Kidney Disease Improving Global Outcomes (KDIGO) working group, but with significantExpand
  • 97
  • 6
Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.
BACKGROUND In chronic kidney disease (CKD) patients, the ability to excrete a phosphate load is impaired. Compensatory increase in parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23)Expand
  • 129
  • 5
High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro.
Phosphate retention plays an important role in the pathogenesis of secondary hyperparathyroidism in patients with renal failure. In in vitro studies, high extracellular phosphate levels directlyExpand
  • 162
  • 5
The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats.
Vitamin D derivatives and calcimimetics are used to treat secondary hyperparathyroidism in patients with chronic renal failure. We investigated the effect of calcitriol, paricalcitol, and theExpand
  • 138
  • 5
A comparison of parathyroid-gland function in haemodialysis patients with different forms of renal osteodystrophy.
Parathyroid function was studied in three different histological forms of renal osteodystrophy: osteitis fibrosa (OF), low-turnover aluminium-associated bone disease (LTAABD), and aplastic boneExpand
  • 66
  • 5